305 related articles for article (PubMed ID: 29652901)
1. Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia.
Saint-Laurent C; Garcia S; Sarrazy V; Dumas K; Authier F; Sore S; Tran A; Gual P; Gennero I; Salles JP; Gouze E
PLoS One; 2018; 13(4):e0195876. PubMed ID: 29652901
[TBL] [Abstract][Full Text] [Related]
2. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
4. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
[TBL] [Abstract][Full Text] [Related]
5. Obesity in achondroplasia patients: from evidence to medical monitoring.
Saint-Laurent C; Garde-Etayo L; Gouze E
Orphanet J Rare Dis; 2019 Nov; 14(1):253. PubMed ID: 31727132
[TBL] [Abstract][Full Text] [Related]
6. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
7. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
8. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
[TBL] [Abstract][Full Text] [Related]
9. Diagnostics and management of sleep-related respiratory disturbances in children with skeletal dysplasia caused by FGFR3 mutations (achondroplasia and hypochondroplasia).
Schlüter B; De Sousa G; Trowitzsch E; Andler W
Georgian Med News; 2011; (196-197):63-72. PubMed ID: 21873755
[TBL] [Abstract][Full Text] [Related]
10. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
11. Severe complications in a child with achondroplasia and two FGFR3 mutations on the same allele.
Rump P; Letteboer TG; Gille JJ; Torringa MJ; Baerts W; van Gestel JP; Verheij JB; van Essen AJ
Am J Med Genet A; 2006 Feb; 140(3):284-90. PubMed ID: 16411219
[TBL] [Abstract][Full Text] [Related]
12. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of MEK1 in chondrocytes causes Stat1-independent achondroplasia-like dwarfism and rescues the Fgfr3-deficient mouse phenotype.
Murakami S; Balmes G; McKinney S; Zhang Z; Givol D; de Crombrugghe B
Genes Dev; 2004 Feb; 18(3):290-305. PubMed ID: 14871928
[TBL] [Abstract][Full Text] [Related]
14. Association of achondroplasia with sagittal synostosis and scaphocephaly in two patients, an underestimated condition?
Accogli A; Pacetti M; Fiaschi P; Pavanello M; Piatelli G; Nuzzi D; Baldi M; Tassano E; Severino MS; Allegri A; Capra V
Am J Med Genet A; 2015 Mar; 167A(3):646-52. PubMed ID: 25691418
[TBL] [Abstract][Full Text] [Related]
15. Achondroplasia: pathogenesis and implications for future treatment.
Laederich MB; Horton WA
Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
[TBL] [Abstract][Full Text] [Related]
16. Circulatory CNP Rescues Craniofacial Hypoplasia in Achondroplasia.
Yamanaka S; Nakao K; Koyama N; Isobe Y; Ueda Y; Kanai Y; Kondo E; Fujii T; Miura M; Yasoda A; Nakao K; Bessho K
J Dent Res; 2017 Dec; 96(13):1526-1534. PubMed ID: 28644737
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 mutation causes abnormal membranous ossification in achondroplasia.
Di Rocco F; Biosse Duplan M; Heuzé Y; Kaci N; Komla-Ebri D; Munnich A; Mugniery E; Benoist-Lasselin C; Legeai-Mallet L
Hum Mol Genet; 2014 Jun; 23(11):2914-25. PubMed ID: 24419316
[TBL] [Abstract][Full Text] [Related]
18. Skeletal Characterization of the Fgfr3 Mouse Model of Achondroplasia Using Micro-CT and MRI Volumetric Imaging.
Shazeeb MS; Cox MK; Gupta A; Tang W; Singh K; Pryce CT; Fogle R; Mu Y; Weber WD; Bangari DS; Ying X; Sabbagh Y
Sci Rep; 2018 Jan; 8(1):469. PubMed ID: 29323153
[TBL] [Abstract][Full Text] [Related]
19. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
20. Molecular defects in achondroplasia and the effects of growth hormone treatment.
Seino Y; Moriwake T; Tanaka H; Inoue M; Kanzaki S; Tanaka T; Matsuo N; Niimi H
Acta Paediatr Suppl; 1999 Feb; 88(428):118-20. PubMed ID: 10102070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
